LEXINGTON, Mass., July 28, 2020 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
of innovative therapeutics for the treatment of cancer, today
announced that the Company will release its second quarter 2020
financial results on Tuesday, August 4,
2020, after the close of US markets. Management will host a
conference call on the same day at 4:30 p.m.
ET.
To access the live conference call, please dial (888) 346-6389
from the United States or (412)
317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can also be
accessed on the Curis website at www.curis.com in the
'Investors' section. A replay of the financial results conference
call will be available on the Curis website shortly after
completion of the call.
About Curis, Inc.
Curis is a biotechnology
company focused on the development of innovative therapeutics for
the treatment of cancer. In 2015, Curis entered into a
collaboration with Aurigene in the areas of immuno-oncology and
precision oncology. As part of this collaboration, Curis has
exclusive licenses to oral small molecule antagonists of immune
checkpoints including, the VISTA/PDL1 antagonist CA-170, and the
TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor,
CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial
in patients with non-Hodgkin lymphoma and in a Phase 1 trial in
patients with acute myeloid leukemia and myelodysplastic syndromes.
In addition, Curis is engaged in a collaboration with ImmuNext for
development of CI-8993, a monoclonal anti-VISTA antibody. Curis is
also party to a collaboration with Genentech, a member of the Roche
Group, under which Genentech and Roche are commercializing
Erivedge® for the treatment of advanced basal cell carcinoma. For
more information, visit Curis' website at www.curis.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/curis-to-release-second-quarter-2020-financial-results-and-hold-conference-call-on-august-4-2020-301100826.html
SOURCE Curis, Inc.